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We were asked by the editors to review “A Check-
list for Retrospective Database Studies” by Brooks
et al. that appears in this issue and to suggest 
additional guidance for manuscript reviewers and
researchers in this ﬁeld. Our review was a joyful
task, because the ISPOR committee that authored
the Checklist performed an excellent service in the
daunting area of longitudinal database research. A
guide such as this one would have been useful in 
the mid-1980s, when epidemiologists and econo-
mists began using claims databases in studies of
drug safety and outcomes research. Unfortunately,
those early researchers had to ﬁnd their way by trial
and error and by building the research tools care-
fully, validating against primary records at each step
of the process. This ISPOR guidance builds on that
groundbreaking work and adds lessons from the
unique challenges encountered in assessing the eco-
nomic impact of therapeutics. 
Research based on retrospective longitudinal
databases is increasingly important to social policy
and clinical decision-making, which needs informa-
tion on “real-world” practice, experience of large
and diverse populations, and efﬁciency in informa-
tion acquisition. The ISPOR Task Force is to be
commended for its careful assessment of the pitfalls
that a diligent reviewer might identify through a
careful manuscript review. In particular, the Check-
list calls attention to three of the most critical issues
in evaluating the quality of the research: 1) Do the
particular claims data used for this study adequately
represent the intended clinical experience? (Is it “ﬁt
for purpose?”); 2) Have linkages across data ﬁles
been managed to assure accuracy of the linkages
themselves and compatibility of the information
across ﬁles? and 3) Have nuances and complexities
of longitudinal data been appreciated, including the
many changes that occur in a given health plan 
and in real patient experiences over time? We would
supplement the Checklist with some additional
points that reviewers (and researchers) should con-
sider. These are listed in the same general order as
the Checklist.
Design and Methods Sections
Reviewers need to understand key aspects of the
data source. In some cases the author may not
include sufﬁcient detail in a manuscript to fully
assess the robustness of the study methods. The 
following issues are critically important in this
assessment:
1. Did the authors utilize the entire available 
calendar time (e.g., the full matrix composed of
practice/plan-time and person-time) or a subset
of the whole? If a subset was used, it is impor-
tant to understand the selection criteria for the
subset to ascertain whether this introduced any
bias.
2. What is the time lag required between occur-
rence of patient encounters and inclusion of
complete information in the available research
database (often many months later)? Often,
some of the most complex and costly claims
may require the longest period for case adjudi-
cation and subsequent inclusion in the data-
base. For some data sources, complete cost
information for hospitals is not available until
3 years after a patient encounter may be
recorded. 
3. How is eligibility information recorded in the
data source (Checklist question 4)? If a data-
base does not include detailed records of eligi-
bility for each member, by types of services
covered, it should probably not be used for lon-
gitudinal research. In addition, are there gaps
in eligibility? If so, how did the researcher
address these gaps? If information is inferred
about events occurring in the intervening
period, is the algorithm clearly provided? What
is the distribution of available follow-up time
in the study population? Often with US claims
data, the average available time is approxi-
mately 9 months. For Medicaid, it can be as
short as 6 months. This limitation not only
inﬂuences the feasibility of using a data source
to answer the research question, but also poten-
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tially inﬂuences the misclassiﬁcation of comor-
bidities and treatment history. One generally
requires more historical data (e.g., greater than
12 months) to characterize patients according
to certain conditions, such as chronic but inter-
mittent ones. 
4. How were referrals handled in the data source?
Sometimes the most costly cases may be treated
in a facility or by a specialist outside the plan.
Those bills may be paid in a different system
and not be captured in the claims database. For
example, if newborns requiring neonatal inten-
sive care are referred to a hospital not in the
plan, the plan may not include speciﬁc claims.
A study of the cost of newborn care would seri-
ously understate the average costs if the most
expensive and most resource-intensive care
were excluded from the database.
5. How is date information about encounters
recorded? Did the author have to work from
billing record dates rather than encounter
dates? If encounter dates are available, how is
it possible to best link physician visits with
medication use? Were episode-grouping algo-
rithms required? If so, how was the algorithm
developed and is there any information on the
validity of the groupings? An episode of care
links together medical care encounters via
claims for payment that document services used
to treat a member for a deﬁned medical condi-
tion over some period of time. The correct def-
inition of episodes should be clear because of
several factors that can inﬂuence the results,
such as the level of incomplete information; use
of billing data; inﬂuence of comorbid condi-
tions, which can make it difﬁcult to infer 
associated treatments and illnesses; and/or an
assumption that patients are homogeneous in
many facets of their illness, including the sever-
ity and consumption of health-care treatments.
In addition, the episode-grouping algorithm
should address how data from different settings
are combined, such as end points in ambulatory
settings, admissions to hospitals, deaths, emer-
gency room visits, and ofﬁce visits.
Analysis Sections
The task force mentions that evidence of a well-
developed a priori analysis plan, preferably with
peer review, should be noted for hypothesis-testing
studies (Checklist question 5). It has been our expe-
rience that only very rarely is a database study
strictly hypothesis-generating or hypothesis-testing.
While the authors are right in wanting an a priori
analysis plan, the reality of database research is that
the design and analysis must often be modiﬁed on
the basis of information only revealed during the
preliminary steps of the analysis. This information
can be key to reﬁning the ﬁnal statistical analysis. 
Operational Deﬁnitions Sections
As is the case in any observational research that
employs archival records, the devil is in the opera-
tional details. The following suggestions supple-
ment the Checklist and relate to the clinical
relevance of the operational deﬁnitions employed in
longitudinal database studies.
1. In addition to considering the implications of
how codes are used to inﬂuence reimburse-
ments and associated misclassiﬁcation (Check-
list question 13), reviewers should understand
any limitations of the coding systems utilized by
the data source. For example, where ICD-9-
CM is utilized, was information available to the
third, fourth, or ﬁfth digit and what are the
implications for the speciﬁcity of classifying a
condition? Did the authors validate the speci-
ﬁcity and sensitivity of the codes against their
clinical deﬁnitions?
2. Did the authors have clinical and operational
deﬁnitions reviewed by clinicians, preferably
clinicians who practice within the health plan
in the study? It is very easy to design a study
that seems to represent medical practice but
fails because of seemingly small but critically
important factors. What was the process of the
clinical review? Did the review allow for exam-
ination into such issues as length of follow-up
needed to observe the events of interest or other
comorbidities or medications important to con-
sider in the analysis? 
3. Is there assurance that all relevant exposures
were measured and that the time windows were
appropriate? In this regard, how do the authors
address the issue of nonspeciﬁc claims that may
be subsequently linked to the condition being
studied? For example, patients often present
with a symptom complex such as jaundice,
which subsequently turns out to be a symptom
of hepatitis C. How did the authors handle 
the period of time between the original pre-
sentation of symptoms and the conﬁrmed 
diagnosis?
4. Are important treatments missing or under-
counted because they were initiated in an 
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inpatient setting? Risks of adverse events and
associated resources are highest at the begin-
ning of a treatment course, which may be initi-
ated in the inpatient setting and only proceed
to outpatient prescribing if successful and safe
in the carefully observed setting. Failure to
identify the initiation of treatment could lead to
underestimation of resource use.
5. Researchers should provide some description of
the suspected or explicit duration of the health
condition in their speciﬁc study population to
assist reviewers in understanding how the study
related to the natural history of the condition.
For example, is the study an incident or incep-
tion cohort of patients newly developing an
illness? If so, how did the authors verify the
lack of disease prior to their assigned index
date? This can be problematic with many
claims data sources where the available follow-
up time is less than 1 year. Alternatively, a
prevalent cohort can be assembled, but the
duration of a condition may not be available,
which can be an important inﬂuence on the
outcome.
Discussion and Conclusions Sections
The Checklist provides excellent guidance for
reviewers as they evaluate the authors’ discussion
and conclusions arising from longitudinal database
studies. In addition to those points, the reviewers
should assess whether the authors compared their
study results to other available studies using retro-
spective data to study a similar condition and other
types of studies on a similar question. If algorithms
have already been developed for identifying medical
conditions or treatment patterns from claims data-
bases, they should be cited and discussed. More-
over, have the authors addressed the inﬂuence of
factors that are not often available in retrospective
data such as smoking, alcohol consumption, body
mass index, or over-the-counter medications and
nonpharmaceutical remedies? 
In a review of the whole manuscript, the authors
should also consider the composition of the
research team, as indicated in the author list and/or
in the description of the research process. Longitu-
dinal database research requires multidisciplinary
skills to translate research questions into testable
hypotheses, to reﬁne and implement study proto-
cols, and to evaluate and discuss results in the
appropriate clinical and policy context. Substantial
input in health outcomes research, clinical care, 
epidemiology, biostatistics, and database program-
ming and analysis are all essential to a successful
study and should be evident in a submitted 
manuscript.
We suggest one further point regarding longitu-
dinal database research. Because it is not realistic 
to include all important protocol and operational
details in a single study manuscript, it would be
useful to the overall research endeavor to make such
details publicly available. For example, the explicit
code groupings and algorithms used to deﬁne a
disease group may differ across studies that reached
different conclusions about the impact of a treat-
ment on resource consumption. Availability of the
detailed protocol and operational procedures on 
a researcher’s Web site would allow further review
across studies and would be useful in the peer-
review process. Moreover, the general sharing of
methodology will accelerate evolution of the ﬁeld of
longitudinal database research.
We appreciate the opportunity to participate in
this important dialogue on the evolving best 
practices of longitudinal database research and
commend the ISPOR Task Force for their excellent
contributions to the ﬁeld.
